临床精神医学杂志
臨床精神醫學雜誌
림상정신의학잡지
JOURNAL OF CLINICAL PSYCHOLOGICAL MEDICINE
2014年
5期
332-334
,共3页
汪卫华%赵汉清%张书友%刘丽%阎同军%钟爱芳
汪衛華%趙漢清%張書友%劉麗%閻同軍%鐘愛芳
왕위화%조한청%장서우%류려%염동군%종애방
抑郁症%瘦素%抗抑郁剂%疗效
抑鬱癥%瘦素%抗抑鬱劑%療效
억욱증%수소%항억욱제%료효
depression%leptin%antidepressant%curative effect
目的:探讨血浆瘦素水平与抗抑郁疗效的相关性。方法:对43例抑郁症患者采用汉密尔顿抑郁量表24项(HAMD)、Beck 绝望量表(BHS)评定抑郁严重程度;测定患者服药前及治疗6周血浆瘦素水平,并以40例体检职工为对照组。结果:不同药物治疗亚组在治疗前后血浆瘦素水平之间差异均无统计学意义(P >0.05)。抑郁症组治疗前血浆瘦素水平[(7.0±3.5)ug/ L]显著低于治疗后[(12.8±5.4)ug/ L])及对照组[(13.4±6.7ug/)L])(P 均<0.01),而抑郁症组治疗后血浆瘦素水平与对照组比较差异无统计学意义(P >0.05)。治疗前血浆瘦素水平与治疗前 HAMD、BHS 评分呈负相关(r 值分别为-0.51、-0.53,P 均<0.01);治疗6周血浆瘦素水平与6周 HAMD、BHS 分呈负相关(r值分别为-0.45、-0.44,P 均<0.01);血浆瘦素水平的变化值与 HAMD、BHS 分的变化值呈负相关(r值分别为-0.40、-0.38,P 均<0.01)。结论:瘦素水平变化与抗抑郁疗效相关,提高血浆瘦素水平的药物可能是一种潜在的新型抗抑郁剂。
目的:探討血漿瘦素水平與抗抑鬱療效的相關性。方法:對43例抑鬱癥患者採用漢密爾頓抑鬱量錶24項(HAMD)、Beck 絕望量錶(BHS)評定抑鬱嚴重程度;測定患者服藥前及治療6週血漿瘦素水平,併以40例體檢職工為對照組。結果:不同藥物治療亞組在治療前後血漿瘦素水平之間差異均無統計學意義(P >0.05)。抑鬱癥組治療前血漿瘦素水平[(7.0±3.5)ug/ L]顯著低于治療後[(12.8±5.4)ug/ L])及對照組[(13.4±6.7ug/)L])(P 均<0.01),而抑鬱癥組治療後血漿瘦素水平與對照組比較差異無統計學意義(P >0.05)。治療前血漿瘦素水平與治療前 HAMD、BHS 評分呈負相關(r 值分彆為-0.51、-0.53,P 均<0.01);治療6週血漿瘦素水平與6週 HAMD、BHS 分呈負相關(r值分彆為-0.45、-0.44,P 均<0.01);血漿瘦素水平的變化值與 HAMD、BHS 分的變化值呈負相關(r值分彆為-0.40、-0.38,P 均<0.01)。結論:瘦素水平變化與抗抑鬱療效相關,提高血漿瘦素水平的藥物可能是一種潛在的新型抗抑鬱劑。
목적:탐토혈장수소수평여항억욱료효적상관성。방법:대43례억욱증환자채용한밀이돈억욱량표24항(HAMD)、Beck 절망량표(BHS)평정억욱엄중정도;측정환자복약전급치료6주혈장수소수평,병이40례체검직공위대조조。결과:불동약물치료아조재치료전후혈장수소수평지간차이균무통계학의의(P >0.05)。억욱증조치료전혈장수소수평[(7.0±3.5)ug/ L]현저저우치료후[(12.8±5.4)ug/ L])급대조조[(13.4±6.7ug/)L])(P 균<0.01),이억욱증조치료후혈장수소수평여대조조비교차이무통계학의의(P >0.05)。치료전혈장수소수평여치료전 HAMD、BHS 평분정부상관(r 치분별위-0.51、-0.53,P 균<0.01);치료6주혈장수소수평여6주 HAMD、BHS 분정부상관(r치분별위-0.45、-0.44,P 균<0.01);혈장수소수평적변화치여 HAMD、BHS 분적변화치정부상관(r치분별위-0.40、-0.38,P 균<0.01)。결론:수소수평변화여항억욱료효상관,제고혈장수소수평적약물가능시일충잠재적신형항억욱제。
Objective:To explore the correlation between the plasma leptin level and antidepressant cur-ative effect. Method:Fouty-three patients with depression were evaluated the severity of symptoms by Hamil-ton depression rating scale-24 items(HAMD)and Beck hopelessness scale(BHS). Forty medical staffs were selected as health control group. Plasma leptin level was detected twice for everyone,before taking pills and after 6 weeks treatment. Results:There were no significant difference between different drug sub groups before and after 6 weeks(P > 0. 05). In depression group,plasma leptin level before taking pills[(7. 0 ± 3. 5)ug/ L]was significantly lower than after 6 weeks treatment[(12. 8 ± 5. 4)ug/ L]as well as the control group[(13. 4 ± 6. 7)ug/ L](all P < 0. 01);after 6 weeks treatment,there was no difference between depressive patient and the control group(P > 0. 05). Before treatment,plasma leptin level showed a negative correlation with scores HAMD and BHS(r = - 0. 51,r = - 0. 53;all P < 0. 01);after 6 weeks treatment,they also had a negative correlation (r = - 0. 40,r = - 0. 38,all P < 0. 01). There was a significantly negative correlation between plasma leptin level and HAMD、BHS scores difference(r = - 0. 40,r = - 0. 38,all P < 0. 01). Conclusion:The change of plasma leptin level has a significant correlation with the antidepressant curative effect;the drug that can increase plasma leptin level may be a potential new antidepressant.